Skip to content
OpenCapital
Get started

Collegium Pharmaceutical, Inc. COLL Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue$188.0MMiss by $3.3M
EPS$1.68Beat by $0.06
Revenue estimate$191.3M
EPS estimate$1.62

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$199.6M
EPS estimate$1.68

Financials

Q2 2025

Income statement

See full
Revenue$188.0M+29.4%
Gross profit$108.4M+19.4%
Operating income$35.1M-26.0%
Net income$12.0M-38.9%
EPS (diluted)$0.34-34.6%

Balance sheet

See full
Cash & equivalents$117.3M-32.1%
Total debt$6.2M-6.6%
Total equity$232.2M+7.2%
Total assets$1.6B+51.2%

Cash flow

See full
Operating cash flow$72.4M+7.5%
CapEx$65.0K-75.9%
Free cash flow$72.4M+7.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$967.8M-8.1%
Enterprise value$856.64M-3.4%
P/E26.7×+16.1×
P/S1.4×-0.5×

Profitability

See full
Gross margin56.7%-5.3pp
Operating margin18.4%-17.0pp
Net margin5.1%-12.2pp
FCF margin29.9%-17.9pp

Returns & leverage

See full
Return on equity16.2%-31.7pp
Debt / equity0×0.0×
Current ratio1.2×+0.1×

Segments

By product

See full
Belbuca$52.6M+0.8%
Jornay PM$32.6M—
Nucynta IR$26.5M+5.2%
Nucynta ER$19.9M+3.5%
Symproic$3.7M-7.7%

By segment

See full
Segment$188.0M+29.4%

Versus estimates

Revenue

Q1 2026$193.5MBeat by $9.0MQ4 2025$205.4MMiss by $913.4KQ3 2025$209.4MBeat by $3.2M
Q2 2025$188.0MMiss by $3.3M
Q1 2025$177.8MBeat by $4.7MQ4 2024$181.9MBeat by $2.3M

Diluted EPS

Q1 2026$1.76Beat by $0.24Q4 2025$2.04Miss by $0.10Q3 2025$2.25Beat by $0.39
Q2 2025$1.68Beat by $0.06
Q1 2025$1.49Beat by $0.06Q4 2024$1.77Beat by $0.23

Ask the moment Collegium Pharmaceutical, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Collegium Pharmaceutical, Inc. report Q2 2025 earnings?
Collegium Pharmaceutical, Inc. (COLL) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Collegium Pharmaceutical, Inc.'s Q2 2025 revenue and EPS?
Collegium Pharmaceutical, Inc. reported revenue of $188.0M and eps of $1.68 for Q2 2025.
Did Collegium Pharmaceutical, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $191.3M by $3.3M. EPS beat the consensus estimate of $1.62 by $0.06.
How did Collegium Pharmaceutical, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 29.4% from $145.3M a year earlier and eps grew 3.7% from $1.62.
Where can I find Collegium Pharmaceutical, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001558370-25-010649) directly on SEC EDGAR. The filing index links above go to sec.gov.